Daniel Podzamczer

Summary

Publications

  1. ncbi request reprint Early virological failure with a combination of tenofovir, didanosine and efavirenz
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    Antivir Ther 10:171-7. 2005
  2. ncbi request reprint Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patients
    Arkaitz Imaz
    HIV Unit, Infectious Diseases Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    AIDS Rev 12:153-63. 2010
  3. ncbi request reprint Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Belvitge, L Hospitalet de Llobregat, Barcelona, Spain
    Curr HIV Res 10:673-8. 2012
  4. ncbi request reprint Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years
    D Podzamczer
    HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, c Feixa Llarga s n L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Curr HIV Res 10:513-20. 2012
  5. doi request reprint Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
    HIV Med 12:374-82. 2011
  6. doi request reprint [Etravirine in highly treatment-experienced patients]
    Daniel Podzamczer Palter
    Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Espana
    Enferm Infecc Microbiol Clin 27:6-11. 2009
  7. ncbi request reprint Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
    Cesar Fisac
    Nutrition Section, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS 19:917-25. 2005
  8. doi request reprint Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study
    Elena Ferrer
    Infectious Disease and Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:931-4. 2008
  9. doi request reprint Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:713-7. 2011
  10. ncbi request reprint Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine
    Elena Ferrer
    Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
    J Infect Dis 187:687-90. 2003

Detail Information

Publications48

  1. ncbi request reprint Early virological failure with a combination of tenofovir, didanosine and efavirenz
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    Antivir Ther 10:171-7. 2005
    ..To describe the occurrence of a high early virological failure (VF) rate and development of resistance mutations in antiretroviral-naive patients receiving tenofovir, didanosine and efavirenz...
  2. ncbi request reprint Community associated methicillin-resistant Staphylococcus aureus in HIV-infected patients
    Arkaitz Imaz
    HIV Unit, Infectious Diseases Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    AIDS Rev 12:153-63. 2010
    ..This article summarizes the current knowledge regarding associated risk factors, clinical manifestations, and management of community-acquired methicillin-resistant Staphylococcus aureus infections in HIV-infected patients...
  3. ncbi request reprint Switching to raltegravir in virologically suppressed in HIV-1-infected patients: a retrospective, multicenter, descriptive study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Belvitge, L Hospitalet de Llobregat, Barcelona, Spain
    Curr HIV Res 10:673-8. 2012
    ..To describe the efficacy and tolerability of switching to raltegravir (RAL) in virologically suppressed HIV-1-infected patients during routine clinical practice...
  4. ncbi request reprint Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years
    D Podzamczer
    HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, c Feixa Llarga s n L Hospitalet de Llobregat, 08907 Barcelona, Spain
    Curr HIV Res 10:513-20. 2012
    ..To evaluate long-term outcomes in patients maintaining a nevirapine (NVP)-based regimen...
  5. doi request reprint Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
    HIV Med 12:374-82. 2011
    ..Lipid profiles and CR from baseline to week 48 are reported...
  6. doi request reprint [Etravirine in highly treatment-experienced patients]
    Daniel Podzamczer Palter
    Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Espana
    Enferm Infecc Microbiol Clin 27:6-11. 2009
    ..Moreover, its long half-life allows once daily administration in patients requiring a QD regimen...
  7. ncbi request reprint Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine
    Cesar Fisac
    Nutrition Section, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS 19:917-25. 2005
    ..To evaluate the 24-month metabolic and morphological benefits obtained from replacing the protease inhibitor (PI) in a regimen with nevirapine, efavirenz or abacavir...
  8. doi request reprint Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study
    Elena Ferrer
    Infectious Disease and Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    AIDS Res Hum Retroviruses 24:931-4. 2008
    ..Larger trials comparing this option with standard initial antiretroviral regimens should be conducted...
  9. doi request reprint Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:713-7. 2011
    ....
  10. ncbi request reprint Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine
    Elena Ferrer
    Infectious Disease Service, Hospital Universitario de Bellvitge, Barcelona, Spain
    J Infect Dis 187:687-90. 2003
    ..At failure, mutations were detected in 7 of 16 patients. An agreement in the results of virtual and real phenotypes was observed in the 93 samples in which both tests were performed...
  11. ncbi request reprint Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    J Acquir Immune Defic Syndr 44:139-47. 2007
    ..To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients...
  12. ncbi request reprint Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function
    Arkaitz Imaz
    HIV Unit, Infectious Diseases Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
    Antivir Ther 18:125-30. 2013
    ..The aim of this study was to assess the short-term and long-term consequences of stopping antiretroviral therapy (ART) in patients with preserved immune function...
  13. doi request reprint Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study
    Josep Mallolas
    Hospital Clinic Universitari IDIBAPS, University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 51:29-36. 2009
    ..To evaluate the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-1-infected patients versus continuing LPV/r...
  14. doi request reprint Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 17:711-8. 2012
    ....
  15. ncbi request reprint Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients
    Esteban Martinez
    Hospital Clinic, Barcelona, Spain
    AIDS 21:367-9. 2007
    ..In contrast, abacavir showed a lower incidence of adverse effects leading to drug discontinuation...
  16. doi request reprint Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz T
    Jose M Miro
    Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    AIDS Res Hum Retroviruses 26:747-57. 2010
    ..At 1 and 3 years, the immune reconstitution induced by an efavirenz-based regimen in very immunosuppressed patients was at least as potent as that induced by a ritonavir-boosted protease inhibitor-based antiretroviral regimen...
  17. doi request reprint Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir
    Maria Saumoy
    Infectious Disease Service, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
    Antivir Ther 16:459-68. 2011
    ....
  18. doi request reprint Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression
    Jose R Santos
    Lluita contra la SIDA, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    HIV Clin Trials 10:432-8. 2009
    ..To assess the Efficacy and safety of switching from HAART containing enfuvirtide to raltegravir as a simplification strategy in patients with viral suppression and intolerance to enfuvirtide...
  19. doi request reprint Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients
    Daniel Podzamczer
    Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    J Acquir Immune Defic Syndr 50:390-6. 2009
    ..The strategy of switching nevirapine (NVP) twice daily to once daily was evaluated...
  20. doi request reprint Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults
    Elena Ferrer
    HIV Unit, Service of Infectious Diseases, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS Res Hum Retroviruses 27:1061-5. 2011
    ..008) and subcutaneous fat (42%, p = 0.008). These data suggest that switching from LPV/r to ATV/r is associated with increased trunk fat, both subcutaneous and visceral...
  21. ncbi request reprint High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain
    HIV Clin Trials 8:193-204. 2007
    ..To investigate the efficacy and safety of high-dose lopinavir/ritonavir (LPV/r) therapy in multiple protease inhibitor, non-nucleoside reverse transcriptase inhibitor (NNRTI)-experienced subjects...
  22. ncbi request reprint Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy
    Xavier Badia
    Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Antivir Ther 9:979-85. 2004
    ..To evaluate health-related quality of life (HRQoL) changes in patients treated with indinavir three-times daily after switching to a twice-daily indinavir/ritonavir regimen or continuing with the same regimen...
  23. doi request reprint LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy
    Maria Saumoy
    HIV Unit, Infectious Disease Service, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, c Feixa Llarga s n, Hospitalet de Llobregat, 08907 Barcelona, Spain
    Atherosclerosis 225:200-7. 2012
    ....
  24. ncbi request reprint A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study
    Cesar Fisac
    Endocrinology Services, Hospital Universitario de Bellvitge, 08907 L Hospitalet de Llobregat, Barcelona, Spain
    J Clin Endocrinol Metab 88:5186-92. 2003
    ..Inclusion of NVP should be considered when deciding upon antiretroviral regimens for patients at high coronary risk...
  25. ncbi request reprint Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less
    Elena Ferrer
    Infectious Disease Services, Universitari de Bellvitge Hospital, Barcelona, Spain
    AIDS 18:1727-9. 2004
    ..More than 80% of patients who continued with nevirapine had viral loads < 50 copies/ml and CD4 cell counts > 200 cells/pl...
  26. doi request reprint Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:2479-86. 2012
    ..To assess the effectiveness of simplification to a dual antiretroviral regimen containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced HIV-1-infected patients...
  27. doi request reprint Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis
    Marylène Lejeune
    Immunology Service, Hospital Clinic Institut d Investigacions Biomèdiques Augustí Pi i Suñer, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 52:662-70. 2011
    ..It is unknown whether a Toxoplasma gondii-specific T cell response is restored after successful combined antiretroviral therapy (cART) in patients with AIDS and current or previous toxoplasmic encephalitis (TE)...
  28. doi request reprint Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients
    Juan Manuel Tiraboschi
    HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    J Acquir Immune Defic Syndr 55:606-9. 2010
    ..To determine maraviroc (MVC) concentrations in cerebrospinal fluid (CSF) in HIV-infected patients...
  29. ncbi request reprint Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine
    Montserrat Plana
    Institut Clinic d Infeccions i Immunologia, Immunology, Infectious Diseases and Microbiology Units, Institut de Investigació Biomèdica Agusti Pi i Suñer, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Antivir Ther 9:197-204. 2004
    ..To evaluate the immunological response in HIV-1-infected, antiretroviral-naive patients receiving highly active antiretroviral therapy regimen of two nucleosides plus a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor...
  30. doi request reprint Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy
    Arkaitz Imaz
    HIV Unit, Infectious Diseases Department, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
    Antivir Ther 17:577-83. 2012
    ..Certain strategies could reduce the emergence of resistance mutations related to TI...
  31. ncbi request reprint Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial
    Jose M Miro
    Institut d Investigacions Biomediques August Pi Sunyer Hospital Clinic, University of Barcelona, Barcelona, Spain
    Clin Infect Dis 43:79-89. 2006
    ..To our knowledge, no randomized trials have evaluated whether prophylaxis against toxoplasmic encephalitis can be safely discontinued after the CD4+ T cell count increases in response to highly active antiretroviral therapy...
  32. doi request reprint How much fat loss is needed for lipoatrophy to become clinically evident?
    Daniel Podzamczer
    Infectious Disease Service, Hospital Universitari de Bellvitge, c Feixa Llarga s n L Hospitalet, Barcelona 08907, Spain
    AIDS Res Hum Retroviruses 25:563-7. 2009
    ..5 kg (sensitivity, 77%; specificity, 76%) and -30% (sensitivity, 85%; specificity, 73%). At least 30% limb fat is needed to be lost in HIV-infected patients for lipoatrophy to become clinically evident...
  33. ncbi request reprint A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study)
    Daniel Podzamczer
    Infectious Disease Service, Ciutat Sanitaria de Bellvitge, L Hospitalet, Barcelona, Spain
    Antivir Ther 7:81-90. 2002
    ....
  34. doi request reprint Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen
    Joaquin Burgos
    Department of Infectious Diseases, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 67:1453-8. 2012
    ..To assess the efficacy and safety of dual-antiretroviral therapy containing a ritonavir-boosted protease inhibitor (PI/r) in treatment-experienced patients failing a current antiretroviral regimen...
  35. ncbi request reprint Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment
    Patricia Barragan
    Hospital Universitari de Bellvitge, Feixa Llarga s n L Hospitalet de Llobregat, 08907, Barcelona, Spain
    Expert Opin Pharmacother 9:2363-75. 2008
    ..Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection...
  36. ncbi request reprint The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy
    Arkaitz Imaz
    HIV Unit, Infectious Diseases Service, Hospital Universitari de Bellvitge, L Hospitalet de Llobregat, Barcelona, Spain
    AIDS Rev 14:268-78. 2012
    ....
  37. doi request reprint Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy
    Adrian Curran
    Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Infectious Diseases Department, Spain
    AIDS 26:475-81. 2012
    ..To compare 48-week changes in body fat distribution and bone mineral density (BMD) between patients switching from a ritonavir-boosted protease inhibitor (PI/r) to raltegravir (RAL) and patients continuing with PI/r...
  38. pmc Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient
    Patricia Barragan
    Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    Am J Trop Med Hyg 83:10-2. 2010
    ..We report the case of a human immunodeficiency virus-1-infected patient who had several relapses of visceral leishmaniasis after treatment with standard therapies and responded to a combined therapy...
  39. doi request reprint Peak bone mass in young HIV-infected patients compared with healthy controls
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Internal Medicine Department, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain Internal Medicine Department, Hospital Sant Pau, Barcelona, Spain Internal Medicine Department, Hospital Bellvitge, Barcelona, Spain Internal Medicine Department, Hospital Clinico San Carlos, Madrid, Spain Internal Medicine Department, Hospital Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain CETIR, Grup Mèdic, Barcelona, Spain Statistics and Operations Research, Technical University of Catalunya, Barcelona, Spain and IrsiCaixa Foundation, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 65:207-12. 2014
    ..Peak bone mass (PBM) is the amount of bone present at the end of skeletal maturation. It is an important determinant of osteoporotic fracture risk. Data on the PBM in the HIV-infected population are lacking...
  40. ncbi request reprint Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group
    Adrian Curran
    Infectious Diseases Department, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Antimicrob Chemother 69:1390-6. 2014
    ..Here, we analyse the effectiveness and safety of PIMT in clinical practice...
  41. ncbi request reprint [Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project]
    Angeles Jaén
    Centre d Estudis Epidemiològics sobre la SIDA de Catalunya CEESCAT, DGSP, Departament de Salut, Badalona, Barcelona, Spain
    Med Clin (Barc) 124:525-31. 2005
    ....
  42. ncbi request reprint Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study
    Vicenc Falco
    Infectious Disease Department, Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Acquir Immune Defic Syndr 49:26-31. 2008
    ....
  43. ncbi request reprint Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy
    Imma Grau
    Infectious Disease Service, Clinical Research Unit, IDIBELL Hospital de Bellvitge and University of Barcelona, Barcelona, Spain
    Arch Intern Med 165:1533-40. 2005
    ..The use of highly active antiretroviral therapy (HAART) may change the incidence of, and the risk and prognostic factors for, invasive pneumococcal disease in patients with human immunodeficiency virus (HIV)...
  44. ncbi request reprint Switching strategies to improve lipid profile and morphologic changes
    Patricia Barragan
    Infectious Disease Service, Hospital Universitari de Bellvitge, L Hospitalet, Barcelona, Spain
    AIDS Rev 8:191-203. 2006
    ..In this setting, switching strategies may be useful to minimize clinical and psychological consequences, improving the quality of life of HIV-infected patients treated with HAART...
  45. doi request reprint Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-γ release assay, and the development of active tuberculosis in HIV-seropositive persons
    Miguel Santin
    Department of Infectious Diseases, Bellvitge University Hospital Institut d Investigació Biomèdica de Bellvitge IDIBELL 08907 Hospitalet de Llobregat, Barcelona, Spain
    Diagn Microbiol Infect Dis 69:59-65. 2011
    ..26 per 100 person-years). Simultaneous testing with TST and QFT-GIT for targeting of chemoprophylaxis, early in the course of HIV infection, might minimize the risk of tuberculosis in these patients...
  46. doi request reprint Fatal bacillary angiomatosis mimicking an infiltrative vascular tumour in the immune restoration phase of an HIV-infected patient
    Oscar Murillo
    HIV Unit, Infectious Diseases Service, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain
    Antivir Ther 17:405-7. 2012
    ..We report an unusual case of fatal Bartonella quintana bacillary angiomatosis occurring in an HIV-infected man during the immune restoration phase...
  47. ncbi request reprint A review of nelfinavir for the treatment of HIV infection
    Montserrat Olmo
    Hospital Universitario de Bellvitge, Infectious Diseases Service, HIV Unit, Hospitalet de Llobregat, Barcelona, Spain
    Expert Opin Drug Metab Toxicol 2:285-300. 2006
    ..In addition, its new simplified posology may contribute to improved adherence...
  48. ncbi request reprint [Recommendations of GESIDA/Spanish National Plan of AIDS on diagnosis and treatment of Kaposi's sarcoma and cervical cancer in HIV-infected patients]
    Daniel Podzamczer
    Ciutat Sanitaria de Bellvitge, L Hospitalet, Barcelona, Spain
    Med Clin (Barc) 118:788-95. 2002